...
首页> 外文期刊>World Journal of Gastroenterology >Synergistic anticancer properties of docosahexaenoic acid and 5-fluorouracil through interference with energy metabolism and cell cycle arrest in human gastric cancer cell line AGS cells
【24h】

Synergistic anticancer properties of docosahexaenoic acid and 5-fluorouracil through interference with energy metabolism and cell cycle arrest in human gastric cancer cell line AGS cells

机译:二十二碳六烯酸和5-氟尿嘧啶通过干扰人胃癌细胞系AGS细胞的能量代谢和细胞周期阻滞而具有协同抗癌特性

获取原文

摘要

AIM: To explore the synergistic effect of docosahexaenoic acid (DHA)/5-fluorouracil (5-FU) on the human gastric cancer cell line AGS and examine the underlying mechanism. METHODS: AGS cells were cultured and treated with a series of concentrations of DHA and 5-FU alone or in combination for 24 and 48 h. To investigate the synergistic effect of DHA and 5-FU on AGS cells, the inhibition of cell proliferation was determined by MTT assay and cell morphology. Flow cytometric analysis was also used to assess cell cycle distribution, and the expression of mitochondrial electron transfer chain complexes (METCs)?I, II and V in AGS cells was further determined by Western blot analysis. RESULTS: DHA and 5-FU alone or in combination could markedly suppress the proliferation of AGS cells in a significant time and dose-dependent manner. DHA markedly strengthened the antiproliferative effect of 5-FU, decreasing the IC50 by 3.56-2.15-fold in an apparent synergy. The morphological changes of the cells were characterized by shrinkage, cell membrane blebbing and decreased adherence. Cell cycle analysis showed a shift of cells into the G0/G1 phase from the S phase following treatment with DHA or 5-FU (G0/G1 phase: 30.04% ± 1.54% vs 49.05% ± 6.41% and 63.39% ± 6.83%, respectively, P 0.05; S phase: 56.76% ± 3.14% vs 34.75% ± 2.35% and 25.63% ± 2.21%, respectively, P 0.05). Combination treatment of DHA and 5-FU resulted in a significantly larger shift toward the G0/G1 phase and subsequent reduction in S phase (G0/G1 phase: 69.06% ± 2.63% vs 49.05% ± 6.41% and 63.39% ± 6.83%, respectively, P 0.05; S phase: 19.80% ± 4.30% vs 34.75% ± 2.35% and 25.63% ± 2.21%, respectively, P 0.05). This synergy was also reflected in the significant downregulation of the expression of METCs in AGS cells. CONCLUSION: Synergistic anticancer properties of DHA and 5-FU may involve interference with energy production of AGS cells via downregulation of METCs and cell cycle arrest.
机译:目的:探讨二十二碳六烯酸(DHA)/ 5-氟尿嘧啶(5-FU)对人胃癌细胞系AGS的协同作用,并探讨其潜在机制。方法:培养AGS细胞,并单独或联合使用一系列浓度的DHA和5-FU处理24和48小时。为了研究DHA和5-FU对AGS细胞的协同作用,通过MTT测定和细胞形态学确定了对细胞增殖的抑制。流式细胞术还用于评估细胞周期分布,并通过蛋白质印迹分析进一步确定了线粒体电子转移链复合物(METCs),I,II和V在AGS细胞中的表达。结果:单独或联合使用DHA和5-FU可以显着抑制时间和剂量依赖性的AGS细胞增殖。 DHA明显增强了5-FU的抗增殖作用,使IC 50 降低了3.56-2.15倍,具有明显的协同作用。细胞的形态变化以收缩,细胞膜起泡和粘附减少为特征。细胞周期分析显示,用DHA或5-FU处理后,细胞从S期移入G0 / G1期(G0 / G1期:30.04%±1.54%,而49.05%±6.41%和63.39%±6.83%,分别为P 0.05; S相:56.76%±3.14%vs 34.75%±2.35%和25.63%±2.21%,P 0.05)。 DHA和5-FU的联合处理导致向G0 / G1相的转移明显更大,随后S减少(G0 / G1相:69.06%±2.63%对49.05%±6.41%和63.39%±6.83%,分别为P 0.05; S相:19.80%±4.30%vs 34.75%±2.35%和25.63%±2.21%,P 0.05)。这种协同作用还反映在AGS细胞中METC表达的显着下调中。结论:DHA和5-FU的协同抗癌特性可能涉及通过下调METCs和细胞周期阻滞来干扰AGS细胞的能量产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号